Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Molecular Targets for Therapy

The prognostic relevance of flt3 and npm1 mutations on older patients treated intensively or non-intensively: a study of 1312 patients in the UK NCRI AML16 trial

Leukemia volume 28, pages 1953–1959 (2014)Cite this article

Subjects

Abstract

Although the prognostic impact of mutations of FLT3 and NPM1 have been extensively studied in younger patients with acute myeloid leukaemia, less is known in older patients whether treated intensively or non-intensively, or in the context of existing prognostic scores. In 1312 patients 16 and 21%, respectively had an FLT3 and NPM1 mutation. An FLT3 mutation did not affect remission rate in intensively or non-intensively treated patients but was associated with an inferior survival. All patients with an NPM1c mutation had a significantly higher remission rate irrespective of treatment approach but survival was not improved, overall, or in any genotype except as in younger patients, in the FLT3 WT NPM1c mutant subgroup. When incorporated into an established multi-parameter prognostic risk score, the molecular information provided additional prognostic definition in 11% of patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Wheatley K, Brookes CL, Howman AJ, Goldstone AH, Milligan DW, Prentice AG et al. Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. Br J Haematol 2009; 145: 598–605.

    Article  Google Scholar 

  2. Sorror ML, Giralt S, Sandmaier BM, de Lima M, Shahjahan M, Maloney DG et al. Hematopoietic cell transplantation-specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood 2007; 110: 4606–4613.

    Article  CAS  Google Scholar 

  3. Kantarjian H, Ravandi F, O’Brien S, Cortes J, Faderl S, Garcia-Manero G et al. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood 2011; 116: 4422–4429.

    Article  Google Scholar 

  4. Malfuson JV, Etienne A, Turlure P, de Revel T, Thomas X, Contentin N et al. Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia. Haematologica 2008; 12: 1806–1813.

    Article  Google Scholar 

  5. Whitman SP, Ruppert AS, Radmacher MD, Mrozek K, Paschka P, Langer C et al. FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood 2008; 111: 1552–1559.

    Article  CAS  Google Scholar 

  6. Gale RE, Green C, Allen C, Mead AJ, Burnett AK, Hills RK et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 2008; 111: 2776–2784.

    Article  CAS  Google Scholar 

  7. Thiede C, Steudel C, Mohr B, Schaich M, Schakel U, Platzbecker U et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002; 99: 4326–4335.

    Article  CAS  Google Scholar 

  8. Schlenk RF, Dohner K, Krauter J, Frohling S, Corbacioglu A, Bullinger L et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358: 1909–1918.

    Article  CAS  Google Scholar 

  9. Kottaridis P, Gale RE, Frew ME, Harrison G, Langabeer S,A, Belton AA et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 Trials. Blood 2001; 98: 1752–1759.

    Article  CAS  Google Scholar 

  10. Schnittger S, Schoch C, Dugas M, Kern W, Staib P, Wuchter C et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002; 100: 59–66.

    Article  CAS  Google Scholar 

  11. Falini B, Bolli N, Liso A, Martelli MP, Mannucci R, Pileri S et al. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications. Leukemia 2009; 23: 1731–1743.

    Article  CAS  Google Scholar 

  12. Mead AJ, Gale RE, Hills RK, Gupta M, Young BD, Burnett AK et al. Conflicting data on the prognostic significance of FLT3/TKD mutations in acute myeloid leukemia might be related to the incidence of biallelic disease. Blood 2008; 112: 444–445.

    Article  CAS  Google Scholar 

  13. Rollig C, Bornhauser M, Thiede C, Taube F, Kramer M, Mohr B et al. Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system. J Clin Oncol 2011; 29: 2758–2765.

    Article  Google Scholar 

  14. Whitman SP, Maharry K, Radmacher MD, Becker H, Mrozek K, Margeson D et al. FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood 2010; 116: 3622–3626.

    Article  CAS  Google Scholar 

  15. Becker H, Marcucci G, Maharry K, Radmacher MD, Mrozek K, Margeson D et al. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B Study. J Clin Oncol 2010; 28: 596–604.

    Article  CAS  Google Scholar 

  16. Scholl S, Theuer C, Scheble V, Kunert C, Heller A, Mugge LO et al. Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia. Eur J Haematol 2008; 80: 208–215.

    Article  CAS  Google Scholar 

  17. Burnett AK, Russell NH, Hills RK, Kell J, Freeman S, Kjeldsen L et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol 2012; 30: 3924–3931.

    Article  CAS  Google Scholar 

  18. Burnett AK, Hills RK, Grimwade D, Jovanovic JV, Craig J, McMullin MF et al. Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 trial. Leukemia 2013; 27: 843–851.

    Article  CAS  Google Scholar 

  19. Burnett AK, Russell NH, Hunter AE, Milligan D, Knapper S, Wheatley K et al. Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival. Blood 2013; 122: 1384–1394.

    Article  CAS  Google Scholar 

  20. Burnett AK, Hills RK, Hunter A, Milligan D, Kell J, Wheatley K et al. The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome. Leukemia 2011; 25: 1122–1127.

    Article  CAS  Google Scholar 

  21. Burnett AK, Russell NH, Culligan D, Cavanagh J, Kell J, Wheatley K et al. The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML. Br J Haematol 2012; 158: 519–522.

    Article  CAS  Google Scholar 

  22. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria treatment outcomes, and reporting standards for therapeutic trials in Acute Myeloid Leukemia. J Clin Oncol 2003; 21: 4642–4649.

    Article  Google Scholar 

  23. Schlenk RF, Dohner K, Kneba M, Gotze K, Hartmann F, Valle F et al. Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B. Haematologica 2009; 94: 54–60.

    Article  CAS  Google Scholar 

  24. Smith CC, Wang Q, Chin CS, Salerno S, Damon LE, Levis MJ et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature 2012; 485: 260–263.

    Article  CAS  Google Scholar 

  25. Baker SD, Zimmerman EI, Wang YD, Orwick S, Zatechka DS, Buaboonnam J et al. Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia. Clin Cancer Res 2013; 19: 5758–5768.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Research in the Cardiff Experimental Cancer Medicine Centre is supported by Cancer Research UK.

Author information

Authors and Affiliations

  1. Department of Haematology, School of Medicine, Cardiff University, Cardiff, UK

    M Lazenby, A F Gilkes, C Marrin, A Evans, R K Hills & A K Burnett

  2. Cardiff Experimental Cancer Medicine Centre, Cardiff, UK

    M Lazenby & A K Burnett

Authors
  1. M Lazenby
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A F Gilkes
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C Marrin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Evans
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R K Hills
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A K Burnett
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A K Burnett.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on the Leukaemia website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lazenby, M., Gilkes, A., Marrin, C. et al. The prognostic relevance of flt3 and npm1 mutations on older patients treated intensively or non-intensively: a study of 1312 patients in the UK NCRI AML16 trial. Leukemia 28, 1953–1959 (2014). https://doi.org/10.1038/leu.2014.90

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2014.90

This article is cited by

Search

Advanced search

Quick links